nabumetone has been researched along with Osteoarthritis, Knee in 7 studies
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.
Osteoarthritis, Knee: Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study found no significant differences in pain relief or tolerability between treatment with SAMe or nabumetone over 8 weeks in Korean patients with knee OA." | 5.14 | Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. ( Cha, HS; Kim, J; Koh, EM; Lee, CK; Lee, EY; Lee, KH; Lee, YJ; Ryu, H; Song, YW; Yoo, B, 2009) |
| " Rofecoxib at a dosage of 12." | 2.72 | Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. ( Geba, GP; Messner, RP; Najarian, DK; Petruschke, RA; Polis, AB; Storms, WW; Tershakovec, AM; Weaver, AL, 2006) |
| " The main safety measure was adverse events during the 6 weeks of treatment." | 2.71 | Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial. ( Baraf, HS; Cohen, SB; Dixon, ME; Geba, GP; Green, JA; Greenwald, MW; Kivitz, AJ; Matsumoto, AK; Moidel, RA; Najarian, DK; Petruschke, RA; Polis, AB, 2004) |
| "Rofecoxib treatment, with its faster onset of OA efficacy and lower rates of related discontinuations, might provide efficacy advantages in the treatment of OA pain." | 2.71 | Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. ( Battisti, WP; Geba, GP; Katz, NP; Kivitz, AJ; Matsumoto, AK; Polis, AB; Weaver, AL, 2004) |
| "Naproxen CR is an effective and tolerable drug in the treatment of knee OA." | 2.70 | Comparison of the efficacy and safety of naproxen CR and nabumetone in the treatment of patients with osteoarthritis of the knee. ( Cha, HS; Jeon, CH; Kim, JS; Koh, EM; Koh, JH; Lee, CK, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, J | 1 |
| Lee, EY | 1 |
| Koh, EM | 2 |
| Cha, HS | 2 |
| Yoo, B | 1 |
| Lee, CK | 2 |
| Lee, YJ | 1 |
| Ryu, H | 1 |
| Lee, KH | 1 |
| Song, YW | 1 |
| Kivitz, AJ | 2 |
| Greenwald, MW | 1 |
| Cohen, SB | 1 |
| Polis, AB | 3 |
| Najarian, DK | 2 |
| Dixon, ME | 1 |
| Moidel, RA | 1 |
| Green, JA | 1 |
| Baraf, HS | 1 |
| Petruschke, RA | 2 |
| Matsumoto, AK | 2 |
| Geba, GP | 3 |
| Battisti, WP | 1 |
| Katz, NP | 1 |
| Weaver, AL | 2 |
| Messner, RP | 1 |
| Storms, WW | 1 |
| Tershakovec, AM | 1 |
| Zhao, SZ | 1 |
| Dedhiya, SD | 1 |
| Bocanegra, TS | 1 |
| Fort, JG | 1 |
| Kuss, ME | 1 |
| Rush, SM | 1 |
| Becvár, R | 1 |
| Urbanová, Z | 1 |
| Vlasáková, V | 1 |
| Vítová, J | 1 |
| Rybár, I | 1 |
| Maldyk, H | 1 |
| Filipowicz-Sosnowska, A | 1 |
| Bernacka, K | 1 |
| Mackiewicz, S | 1 |
| Gömör, B | 1 |
| Rojkovich, B | 1 |
| Siro, B | 1 |
| Bereczki, J | 1 |
| Toth, K | 1 |
| Sukenik, S | 1 |
| Green, L | 1 |
| Ehrenfeld, M | 1 |
| Pavelka, K | 1 |
| Koh, JH | 1 |
| Jeon, CH | 1 |
| Kim, JS | 1 |
7 trials available for nabumetone and Osteoarthritis, Knee
| Article | Year |
|---|---|
Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients.
Topics: Aged; Analgesics; Anti-Inflammatory Agents; Asian People; Butanones; Double-Blind Method; Female; Hu | 2009 |
Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxygenase I | 2004 |
Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Butano | 2004 |
Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxygenase 2 Inhibitor | 2006 |
Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Female; Humans; Male; Middle Aged; Nabumet | 1999 |
Nabumetone induces less gastrointestinal mucosal changes than diclofenac retard.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Dicl | 1999 |
Comparison of the efficacy and safety of naproxen CR and nabumetone in the treatment of patients with osteoarthritis of the knee.
Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Constipation; | 2001 |